Last reviewed · How we verify
NCT01109433
Immunogenetic Mechanisms in Behcet's Disease
trial in Behcet's Disease in 25 participants. Terminated before completion.
Quick facts
| Lead sponsor | National Eye Institute (NEI) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 15 April 2010 |
| Estimated completion | 17 December 2018 |
| Sites | 1 location across United States |
Conditions studied
- Behcet's Disease — all drugs for Behcet's Disease →
- Uveitis — all drugs for Uveitis →
Sponsor
National Eye Institute (NEI)
Who can join
Eligibility, any sex, with Behcet's Disease or Uveitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases of legal blindness every year. Uveitis can be caused by Beh(SqrRoot)(Beta)et s disease (BD), a chronic inflammatory disorder that can affect the eye, mucous membranes, and other body organs such as the joints, intestinal tract, blood vessels, and central nervous system. Objectives: The purpose of this study is to see how genes affect Beh(SqrRoot)(Beta)et s disease and if there are differences in Beh(SqrRoot)(Beta)et s disease among people of different backgrounds. Eligibility: * Individuals who have a diagnosis of BD and are enrolled in another NIH study. * Individuals who are willing to donate blood for the purposes of this research study and who are willing to have their blood stored for possible future/other research purposes. Design: * As part of the study, blood samples will be drawn from participants when an exacerbation in disease activity occurs and before and after any significant change in treatment for BD. * No treatments will be provided in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01109433
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
- NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
- NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease · Phase 1 · recruiting
- NCT04833361 — Potential Environmental Causes of Uveal Coloboma · completed
- NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss · NA · active not recruiting
- NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01109433 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
- Last refreshed: 4 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01109433.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing